{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:58:13Z","timestamp":1768881493980,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40268-018-0254-8","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T13:17:31Z","timestamp":1542115051000},"page":"271-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?"],"prefix":"10.1007","volume":"18","author":[{"given":"Kyle M.","family":"Gardiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Tett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine E.","family":"Staatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"254_CR1","first-page":"1361","volume":"12","author":"M Wagner","year":"2015","unstructured":"Wagner M, Earley AK, Webster AC, et al. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2015;12:1361\u20136137.","journal-title":"Cochrane Database Syst Rev"},{"key":"254_CR2","first-page":"1","volume":"38","author":"Australia and New Zealand Dialysis and Transplant Registry","year":"2016","unstructured":"Australia and New Zealand Dialysis and Transplant Registry. Thirty Eighth Annual Report: Chapter 8. Transplantation. 2016;38:1\u201321.","journal-title":"Transplantation"},{"key":"254_CR3","first-page":"115","volume":"132","author":"F Caskey","year":"2016","unstructured":"Caskey F, Castledine C, Dawnay A, et al. 18th Annual Report of the Renal Association. Nephron. 2016;132:115\u201331.","journal-title":"Nephron"},{"issue":"3 suppl 1","key":"254_CR4","first-page":"S1","volume":"67","author":"R Saran","year":"2016","unstructured":"Saran R, Li Y, Robinson B. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2016;67(3 suppl 1):S1\u2013305.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"254_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","volume":"4","author":"HU Meier-Kriesche","year":"2004","unstructured":"Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transpl. 2004;4(3):378\u201383.","journal-title":"Am J Transpl"},{"issue":"2","key":"254_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","volume":"12","author":"J Sellares","year":"2012","unstructured":"Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transpl. 2012;12(2):388\u201399.","journal-title":"Am J Transpl"},{"issue":"9","key":"254_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00002018-200124090-00002","volume":"24","author":"M Behrend","year":"2001","unstructured":"Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 2001;24(9):645\u201363.","journal-title":"Drug Saf"},{"issue":"3","key":"254_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1034\/j.1399-0012.2003.00026.x","volume":"17","author":"RP Pelletier","year":"2003","unstructured":"Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transpl. 2003;17(3):200\u20135.","journal-title":"Clin Transpl"},{"issue":"6","key":"254_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1399-0012.2005.00421.x","volume":"19","author":"JC Tierce","year":"2005","unstructured":"Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transpl. 2005;19(6):779\u201384.","journal-title":"Clin Transpl"},{"issue":"11","key":"254_CR10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2165\/00019053-200826110-00007","volume":"26","author":"G Machnicki","year":"2008","unstructured":"Machnicki G, Ricci JF, Brennan DC, et al. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients. Pharmacoeconomics. 2008;26(11):951\u201367.","journal-title":"Pharmacoeconomics"},{"key":"254_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/IJNRD.S58206","volume":"7","author":"F Rivera","year":"2014","unstructured":"Rivera F, Anaya S. Lupus nephritis flare in young patients: relapse or nonadherence to treatment? Int J Nephrol Renovasc Dis. 2014;7:117\u201321.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"254_CR12","unstructured":"Roche Pharmaceuticals. CellCept\u00ae Product Information; 2012. http:\/\/www.roche-australia.com\/content\/dam\/internet\/corporate\/roche\/en_AU\/files\/transplant\/cellcept-pi.pdf . Accessed 25 Nov 2017."},{"key":"254_CR13","unstructured":"Novartis Australia. Myfortic\u00ae Product Information; 2012. http:\/\/www.tga.gov.au\/pdf\/auspar\/auspar-mycophenolate-sodium-130517-pi.pdf . Accessed 25 Nov 2017."},{"issue":"S1","key":"254_CR14","first-page":"21","volume":"17","author":"U.S. Department of Health and Human Services","year":"2017","unstructured":"U.S. Department of Health and Human Services. OPTN\/SRTR 2015 Annual Data Report. Kidney Am J Transpl. 2017;17(S1):21\u2013116.","journal-title":"Kidney Am J Transpl"},{"key":"254_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12659\/AOT.895664","volume":"21","author":"KM Gardiner","year":"2016","unstructured":"Gardiner KM, Tett SE, Staatz CE. Multinational evaluation of mycophenolic acid, tacrolimus, cyclosporin, sirolimus, and everolimus utilization. Ann Transpl. 2016;21:1\u201311.","journal-title":"Ann Transpl"},{"key":"254_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"4","key":"254_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u2013269, w264.","journal-title":"Ann Intern Med"},{"issue":"2","key":"254_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1600-6143.2003.00321.x","volume":"4","author":"K Budde","year":"2004","unstructured":"Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transpl. 2004;4(2):237\u201343.","journal-title":"Am J Transpl"},{"issue":"2","key":"254_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1600-6143.2003.00337.x","volume":"4","author":"M Salvadori","year":"2004","unstructured":"Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transpl. 2004;4(2):231\u20136.","journal-title":"Am J Transpl"},{"issue":"10","key":"254_CR20","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/ndt\/gfi009","volume":"20","author":"N Kamar","year":"2005","unstructured":"Kamar N, Oufroukhi L, Faure P, et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transpl. 2005;20(10):2231\u20136.","journal-title":"Nephrol Dial Transpl"},{"issue":"8","key":"254_CR21","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.transproceed.2006.08.085","volume":"38","author":"N Calvo","year":"2006","unstructured":"Calvo N, Sanchez-Fructuoso AI, Conesa J, et al. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium. Transpl Proc. 2006;38(8):2396\u20137.","journal-title":"Transpl Proc"},{"issue":"9","key":"254_CR22","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/01.tp.0000209411.66790.b3","volume":"81","author":"L Chan","year":"2006","unstructured":"Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation. 2006;81(9):1290\u20137.","journal-title":"Transplantation"},{"issue":"9","key":"254_CR23","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/lt.20792","volume":"12","author":"J Dumortier","year":"2006","unstructured":"Dumortier J, Gagnieu MC, Salandre J, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transpl. 2006;12(9):1342\u20136.","journal-title":"Liver Transpl"},{"issue":"8","key":"254_CR24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.healun.2006.04.005","volume":"25","author":"JA Kobashigawa","year":"2006","unstructured":"Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, Myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transpl. 2006;25(8):935\u201341.","journal-title":"J Heart Lung Transpl"},{"issue":"11","key":"254_CR25","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/01.tp.0000290678.06523.95","volume":"84","author":"P Bolin","year":"2007","unstructured":"Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation. 2007;84(11):1443\u201351.","journal-title":"Transplantation"},{"issue":"7","key":"254_CR26","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.transproceed.2007.07.012","volume":"39","author":"F Cofan","year":"2007","unstructured":"Cofan F, Rosich E, Arias M, et al. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transpl Proc. 2007;39(7):2179\u201381.","journal-title":"Transpl Proc"},{"issue":"7","key":"254_CR27","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.transproceed.2008.07.041","volume":"40","author":"P Darji","year":"2008","unstructured":"Darji P, Vijayaraghavan R, Thiagarajan CM, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transpl Proc. 2008;40(7):2262\u20137.","journal-title":"Transpl Proc"},{"issue":"6","key":"254_CR28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1399-3046.2007.00831.x","volume":"12","author":"L Pape","year":"2008","unstructured":"Pape L, Ahlenstiel T, Kreuzer M, et al. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transpl. 2008;12(6):640\u20132.","journal-title":"Pediatr Transpl"},{"issue":"6","key":"254_CR29","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.transproceed.2009.06.004","volume":"41","author":"L Barrera-Pulido","year":"2009","unstructured":"Barrera-Pulido L, Alamo-Mart\u00ednez JM, Mar\u00edn-G\u00f3mez LM, et al. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications. Transpl Proc. 2009;41(6):2192\u20134.","journal-title":"Transpl Proc"},{"issue":"9","key":"254_CR30","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1016\/j.transproceed.2009.06.183","volume":"41","author":"JF Bilodeau","year":"2009","unstructured":"Bilodeau JF, Montambault P, Wolff JL, et al. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transpl Proc. 2009;41(9):3683\u20139.","journal-title":"Transpl Proc"},{"issue":"10","key":"254_CR31","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1016\/j.transproceed.2009.08.078","volume":"41","author":"M Burg","year":"2009","unstructured":"Burg M, S\u00e4emann MD, Wieser C, et al. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients. Transpl Proc. 2009;41(10):4159\u201364.","journal-title":"Transpl Proc"},{"issue":"2","key":"254_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1399-3046.2008.00977.x","volume":"13","author":"R De Paula Meneses","year":"2009","unstructured":"De Paula Meneses R, Halusch Kotsifas C. Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in pediatric renal transplant patients with stable graft function. Pediatr Transpl. 2009;13(2):188\u201393.","journal-title":"Pediatr Transpl"},{"issue":"6","key":"254_CR33","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/j.1399-0012.2009.01019.x","volume":"23","author":"C Doria","year":"2009","unstructured":"Doria C, Ramirez CB, Frank AM, et al. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil. Clin Transpl. 2009;23(6):882\u20136.","journal-title":"Clin Transpl"},{"issue":"2","key":"254_CR34","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.transproceed.2008.12.021","volume":"41","author":"G Robaeys","year":"2009","unstructured":"Robaeys G, Cassiman D, Verslype C, et al. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects. Transpl Proc. 2009;41(2):610\u20133.","journal-title":"Transpl Proc"},{"issue":"5","key":"254_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1472-8206.2009.00711.x","volume":"23","author":"M Sabbatini","year":"2009","unstructured":"Sabbatini M, Capone D, Gallo R, et al. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol. 2009;23(5):617\u201324.","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"254_CR36","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1432-2277.2009.00877.x","volume":"22","author":"M Shehata","year":"2009","unstructured":"Shehata M, Bhandari S, Venkat-Raman G, et al. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transpl Int. 2009;22(8):821\u201330.","journal-title":"Transpl Int"},{"issue":"12","key":"254_CR37","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3346\/jkms.2010.25.12.1759","volume":"25","author":"HS Hwang","year":"2010","unstructured":"Hwang HS, Hyoung BJ, Kim S, et al. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus. J Korean Med Sci. 2010;25(12):1759\u201365.","journal-title":"J Korean Med Sci"},{"issue":"6","key":"254_CR38","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1399-3046.2010.01326.x","volume":"14","author":"H Reyes","year":"2010","unstructured":"Reyes H, Hern\u00e1ndez AM, Valverde S, et al. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. Pediatr Transpl. 2010;14(6):746\u201352.","journal-title":"Pediatr Transpl"},{"issue":"4","key":"254_CR39","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/TP.0b013e318205568c","volume":"91","author":"AJ Langone","year":"2011","unstructured":"Langone AJ, Chan L, Bolin P, et al. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. Transplantation. 2011;91(4):470\u20138.","journal-title":"Transplantation"},{"issue":"4","key":"254_CR40","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/TP.0b013e31822527ca","volume":"92","author":"F Ortega","year":"2011","unstructured":"Ortega F, S\u00e1nchez-Fructuoso A, Cruzado JM, et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation. 2011;92(4):426\u201332.","journal-title":"Transplantation"},{"issue":"5","key":"254_CR41","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.transproceed.2011.01.184","volume":"43","author":"P Reinke","year":"2011","unstructured":"Reinke P, Budde K, Hugo C, et al. Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transpl Proc. 2011;43(5):1641\u20136.","journal-title":"Transpl Proc"},{"issue":"1","key":"254_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1399-0012.2011.01444.x","volume":"26","author":"AH Toledo","year":"2012","unstructured":"Toledo AH, Hendrix L, Buchholz V, et al. Improvement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients. Clin Transpl. 2012;26(1):156\u201363.","journal-title":"Clin Transpl"},{"issue":"2","key":"254_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000365360","volume":"40","author":"S Bunnapradist","year":"2014","unstructured":"Bunnapradist S, Sampaio MS, Wilkinson AH, et al. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. Am J Nephrol. 2014;40(2):184\u201390.","journal-title":"Am J Nephrol"},{"issue":"7","key":"254_CR44","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/ctr.12379","volume":"28","author":"R Lopez-Solis","year":"2014","unstructured":"Lopez-Solis R, DeVera M, Steel J, et al. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil. Clin Transpl. 2014;28(7):783\u20138.","journal-title":"Clin Transpl"},{"issue":"1","key":"254_CR45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.transproceed.2013.09.026","volume":"46","author":"M Sterneck","year":"2014","unstructured":"Sterneck M, Settmacher U, Ganten T, et al. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients. Transpl Proc. 2014;46(1):234\u201340.","journal-title":"Transpl Proc"},{"key":"254_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/CEG.S81922","volume":"8","author":"B Manger","year":"2015","unstructured":"Manger B, Hiepe F, Schneider M, et al. Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a phase III, open-label, single-arm, multicenter study. Clin Exp Gastroenterol. 2015;8:205\u201313.","journal-title":"Clin Exp Gastroenterol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-018-0254-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0254-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0254-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T22:10:33Z","timestamp":1662415833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-018-0254-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["254"],"URL":"https:\/\/doi.org\/10.1007\/s40268-018-0254-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"13 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Kyle Gardiner, Susan Tett and Christine Staatz declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}